Filing Flows › Crispr Therapeutics AG (CRSP) › Collaboration Revenue revenue
Crispr Therapeutics AG (CRSP) Collaboration Revenue revenue by quarter
Crispr Therapeutics AG's Collaboration Revenue revenue was $12.3M in Q3 2026 (third quarter 2026), +23% from Q2 2026. Over the last 3 quarters it ranged from $1.0M (Q1 2026) to $12.3M (Q3 2026).
| Quarter | Collaboration Revenue revenue | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $12.3M | +23% | — |
| Q2 2026 | $10.0M | +900% | — |
| Q1 2026 | $1.0M | — | — |
Q3 2026 at a glance
Crispr Therapeutics AG, Q3 2026: revenue $12.7M (14× year over year), net loss $111M, operating cash flow −$89.7M. The chart follows the revenue to costs, profit and cash.
Questions
What is Crispr Therapeutics AG's Collaboration Revenue revenue?
Crispr Therapeutics AG's Collaboration Revenue revenue was $12.3M in Q3 2026 (third quarter 2026), +23% from Q2 2026.
How has Crispr Therapeutics AG's Collaboration Revenue revenue changed?
Over the last 3 quarters it ranged from $1.0M (Q1 2026) to $12.3M (Q3 2026).
Q3 2026 results → · How Crispr Therapeutics AG makes money →